{"id":"NCT00266695","sponsor":"Chromaderm, Inc.","briefTitle":"Treatment for Completers of the Study B7A-MC-MBCM","officialTitle":"Open-Label Treatment for Patients Completing Study B7A-MC-MBCM","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2005-12-19","resultsPosted":"2016-01-28","lastUpdate":"2016-10-06"},"enrollment":203,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"Ruboxistaurin","otherNames":["LY 333531","Arxxant"]}],"arms":[{"label":"Ruboxistaurin","type":"EXPERIMENTAL"}],"summary":"To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.","primaryOutcome":{"measure":"Sustained Moderate Visual Loss (SMVL)","timeFrame":"Baseline, 18 months up to 24 months","effectByArm":[{"arm":"Ruboxistaurin","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":203},"commonTop":["Retinal laser coagulation","Nasopharyngitis","Vitreous haemorrhage","Back pain","Diarrhoea"]}}